Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 2/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.39 |
| ▸ | HRH2 | P25021 | 3/20 | 0.38 |
| ▸ | HRH1 | P35367 | 3/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL27805378 | 0.98 | CXCR4 (0.46) | CXCR4SIGMAR1HRH2HRH1HRH3 | |
| SCHEMBL272713 | 0.94 | CXCR4 (0.46) | CXCR4SIGMAR1HRH2HRH1HRH3 | |
| SCHEMBL5293272 | 0.86 | SIGMAR1 (0.41) | CXCR4SIGMAR1HRH2HRH1HRH3 | |
| SCHEMBL5290984 | 0.84 | MEN1 (0.44) | CXCR4SIGMAR1HRH2HRH1HRH3 | |
| SCHEMBL28866652 | 0.82 | HRH3 (0.50) | HRH3ALDH1A1LMNAKDM4EMEN1 | |
| SCHEMBL26488889 | 0.81 | HRH3 (0.54) | HRH3SMN1; SMN2MEN1KMT2A | |
| SCHEMBL8561719 | 0.81 | HRH3 (0.54) | HRH3SMN1; SMN2MEN1KMT2A | |
| SCHEMBL8614873 | 0.77 | CXCR4 (0.70) | CXCR4SIGMAR1HRH2HRH1HRH3 | |
| SCHEMBL5946012 | 0.76 | HRH3 (0.46) | HRH3ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL15718696 | 0.76 | HRH3 (0.41) | HRH3ALDH1A1KDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108884271-A | MODIFIER AND MODIFIED CONJUGATED DIENE-BASED POLYMER CONTAINING FUNCTIONAL GROUP DERIVED THEREFROM | 株式会社LG化学 | 2018-11-23 | — | — | CN | disclosed |
| CN-101663293-B | Quinoline-carboxamide derivatives as p2y12 antagonists | SANOFI AVENTIS SPA | 2013-07-31 | — | — | CN | disclosed |
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| CN-101522629-B | 2-aminocarbonyl-pyridine derivatives | ACTELION PHARMACEUTICALS LTD | 2012-07-18 | — | — | CN | disclosed |
| CN-101528715-B | 2-phenyl-6-aminocarbonyl-pyrimidine derivatives | ACTELION PHARMACEUTICALS LTD | 2011-08-24 | — | — | CN | disclosed |
| CN-101663293-A | Quinoline-carboxamide derivatives as p2y12 antagonists | SANOFI AVENTIS | 2010-03-03 | — | — | CN | disclosed |
| CN-101528715-A | 2-phenyl-6-aminocarbonyl-pyrimidine derivatives | ACTELION PHARMACEUTICALS LTD (CH) | 2009-09-09 | — | — | CN | disclosed |
| CN-101522629-A | 2-aminocarbonyl-pyridine derivatives | ACTELION PHARMACEUTICALS LTD (CH) | 2009-09-02 | — | — | CN | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | CXCR4 629/4885SIGMAR1 234/4885HRH2 730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.